Citius Pharmaceuticals (CTXR) Receivables - Accured (2016)
Citius Pharmaceuticals' (CTXR) quarterly Receivables - Accured came in at $17.5 million in Q3 2016.
Citius Pharmaceuticals (CTXR) Receivables - Accured (2016) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 1 years of Receivables - Accured data on file, last reported at $17.5 million in Q3 2016.
- Quarterly Receivables - Accured changed N/A year-over-year to $17.5 million in Q3 2016, while the trailing twelve-month figure through Sep 2016 was $17.5 million (changed N/A YoY) and the FY2016 annual result came in at $17.5 million, changed N/A from the prior year.
- Receivables - Accured held at $17.5 million in Q3 2016.
- In the past five years, Receivables - Accured ranged from a high of $17.5 million in Q3 2016 to a low of $17.5 million in Q3 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables - Accured (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | - |
| 10 | Citius Pharmaceuticals | 15.82 Mn | 15.82 Mn | 1.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2016 | 17.48 Mn |
| Sep 30, 2016 | 17.48 Mn |